Evommune Analyst Price Targets

Wall Street analyst price targets and consensus rating for Evommune (EVMN).

Price Target Range — 4 Quarters

Analyst Consensus — 11 Analysts

1S.Buy

8Buy

2Hold

Consensus RatingOutperform# Analysts11Avg. Consensus PT$34Upside to Avg. PT+444.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Leerink Partners	Thomas Smith	PT Cut	Outperform	$28→$22
Sep 9, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$29→$21
Sep 9, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 26, 2026	Needham	Serge Belanger	Initiate	Buy	$28
Aug 7, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$30→$29
Aug 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Jun 30, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$55→$26
Jun 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
Jun 29, 2026	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
May 26, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$50
May 11, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$54→$55
Apr 10, 2026	RBC Capital	Brian Abrahams	Maintained	Outperform	$48
Mar 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$65→$50
Mar 18, 2026	Clear Street	Kaveri Pohlman	Initiate	Buy	$53
Feb 10, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$35→$65
Jan 22, 2026	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$42
Jan 8, 2026	Raymond James	Martin Auster	Initiate	Strong Buy	$40
Jan 6, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$35
Dec 1, 2025	William Blair	Matt Phipps	Initiate	Outperform	—
Dec 1, 2025	Cantor Fitzgerald	Prakhar Agrawal	Initiate	Overweight	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) from Neutral to Neutral.

Benzinga Newsdesk

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts

Avi Kapoor

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29

RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $30 to $29.

Benzinga Newsdesk

Evommune Inc

Evommune Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29

People Also Watch

People Also Watch

Evommune Inc

Evommune Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRORBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PROHC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRONeedham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

PRORBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29